Non-anticoagulant derivatives of heparin for the management of asthma: Distant dream or close reality~

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 357-373

  Shastri, Madhur D ^a   Peterson, Gregory M ^a   Stewart, Niall ^a   Sohal, Sukhwinder Singh ^a   Patel, Rahul P ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Anti inflammatory; Anticoagulant oligosaccharides; Asthma; Bleeding; Heparin; Low molecular weight heparin; Non anticoagulant oligosaccharides

Indexed keywords

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; HEPARIN; HUMANS;

EID: 84894080723     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.866092     Document Type: Review

References (127)

1. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-63
2. Ogura H, Hasegawa A, Suami T. Carbohydrates: Synthetic methods and applications in medicinal chemistry. Kodansha; Tokyo: 1992
3. Lane DA, Lindahl U. Heparin: Chemical and biological properties, clinical applications. Edward Arnold; London: 1989
4. Hoppensteadt D, Walenga JM, Fareed J, et al. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: Basic and clinical differentiation. Hematol Oncol Clin North Am 2003;17:313-42
5. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001;57:159-206
6. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74
7. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;126:188S-203S
8. Turpie AG. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg 1991;161:532-6
9. Samama CM, Barre E, Combe S, et al. A pilot study on the use of a low molecular weight heparin (Enoxaparin) in arterial reconstructive surgery. Semin Thromb Hemost 1991;17:367-70
10. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976;69:570-7
11. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: Host-Associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22
12. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: Potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208
13. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-8
14. Casu B, Petitou M, Provasoli M, et al. Conformational flexibility: A new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 1988;13:221-5
15. Garg HG, Yu L, Hales CA, et al. Sulfation patterns in heparin and heparan sulfate: Effects on the proliferation of bovine pulmonary artery smooth muscle cells. Biochim Biophys Acta 2003;1639:225-31
16. Ishihara M. Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2. Glycobiology 1994;4:817-24
17. Ono K, Hattori H, Takeshita S, et al. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999;9:705-11
18. Shifren A, Witt C, Christie C, et al. Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo) 2012;2012:316049
19. Ozier A, Allard B, Bara I, et al. The pivotal role of airway smooth muscle in asthma pathophysiology. Hindawi Publishing Corporation; J Allergy (Cairo) 2011, doi:10.1155/2011/742710
20. Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999;104:1001-6
21. Jarjour NN, Kelly E. Pathogenesis of asthma. Med Clin North Am 2002;86:925
22. Grootendorst D, Sont J, Willems L, et al. Comparison of inflammatory cell counts in asthma: Induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997;27:769-79
23. Bloemen K, Verstraelen S, Van Den Heuvel R, et al. The allergic cascade: Review of the most important molecules in the asthmatic lung. Immunol Lett 2007;113:6-18
24. Holgate ST, Davies DE, Lackie PM, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin immunol 2000;105:193-204
25. Holt PG. Antigen presentation in the lung. Am J Respir Crit Care Med 2000;162:S151-S56
26. Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999;402:18-23
27. Corrigan C, Kay A. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992;13:501-7
28. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin immunol 2001;108:S65-71
29. Bradding P, Holgate ST. Immunopathology and human mast cell cytokines. Crit Rev Oncol Hematol 1999;31:119
30. Parameswaran K, Willems-Widyastuti A, Alagappan VK, et al. Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys 2006;44:139-46
31. Boxall C, Holgate S, Davies D. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur Respir J 2006;27:208-29
32. Nader H, Dietrich C. Natural occurrence and possible biological role of heparin. In: Lane D, Lindahl U, editors. Heparin: Chemical and biological properties, clinical applications. Edward Arnold; London: 1989. p. 81-96
33. Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind Land P-selectin and inhibit acute inflammation. Blood 1993;82:3253-8
34. Lasser E, Simon R, Lyon S, et al. Heparin-like anticoagulants in asthma. Allergy 1987;42:619-25
35. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am J Respir Crit Care Med 1993;147:160-3
36. Brown RA, Allegra L, Matera MG, et al. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 2006;19:419-24
37. Lider O, Mekori YA, Miller T, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990;20:493-9
38. Sasaki M, Herd CM, Page CP. Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 1993;110:107-12
39. Okona-Mensah K, Shittu E, Page C, et al. Inhibition of serum and transforming growth factor beta (TGF-beta1)-induced DNA synthesis in confluent airway smooth muscle by heparin. Br J Pharmacol 1998;125:599-606
40. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993;329:90-5
41. Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 1999;160:576-81
42. Diamant Z, Timmers MC, Van der Veen H, et al. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996;153:1790-5
43. Motojima S, Frigas E, Loegering DA, et al. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am J Respir Crit Care Med 1989;139:801-5
44. Venge R, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ECP): Molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29:1172-86
45. Bock P, Luscombe M, Marshall S, et al. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 1980;191:769
46. Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009;105:223-30
47. Lever R, Hoult JRS, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-40
48. Silvestro L, Viano I, Macario M, et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost 1994;20:254-8
49. Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-And P-selectins. J Clin Invest 2002;110:127-36
50. Lakshmi T, Shanmugasundaram N, Shanmuganathan S, et al. Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin. J Biomed Mater Res A 2010;95:118-28
51. Peter K, Schwarz M, Conradt C, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/ CD18). Circulation 1999;100:1533-9
52. Forrest M, Paulson JC. Selectin family of adhesion molecules. In: Granger DN, Schmid-Schoenbein GW, editors. Physiology and pathophisiology of leukocyte adhesion. Oxford University Press; New York: 1995. p. 43-82
53. Koenig A, Norgard-Sumnicht K, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-89
54. Skinner MP, Lucas C, Burns G, et al. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 1991;266:5371-4
55. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 1991;65:859-73
56. Adams DH, Rlloyd A. Chemokines: Leucocyte recruitment and activation cytokines. Lancet 1997;349:490-5
57. Johnson Z, Proudfoot A, Handel T. Interaction of chemokines and glycosaminoglycans: A new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005;16:625-36
58. Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001;14:249-54
59. Kuschert GS, Coulin F, Power CA, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68
60. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-Anticoagulant heparin species. Blood 1987;70:551-7
61. Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99
62. Barnes PJ, Karin M. Nuclear Factor-KappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71
63. Gagliardo R, Chanez P, Mathieu M, et al. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 2003;168:1190-8
64. Li X, Zheng Z, Ma X. Unfractionated heparin inhibits lipopolysaccharideinduced inflammatory response through blocking p38 MAPK and NF-kappaB activation on endothelial cell. Cytokine 2012;60:114-21
65. Hecht I, Hershkoviz R, Shivtiel S, et al. Heparin-disaccharide affects T cells: Inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol 2004;75:1139-46
66. Lucio J, D'Brot J, Guo C, et al. Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol 1992;73:1093-101
67. Page C. One explanation of the asthma paradox: Inhibition of natural antiinflammatory mechanism by b2-Agonists. Lancet 1991;337:717-20
68. Bissonnette E, Befus A. Mast cells in asthma. Can Respir J 1998;5:23
69. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1alpha, IL-1beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992;22:3027-31
70. Ji S-L, Cui H-F, Shi F, et al. Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes. World J Gastroenterol 2004;10:3490-4
71. Ramdin L, Perks B, Sheron N, et al. Regulation of interleukin-8 binding and function by heparin and a2-macroglobulin. Clin Exp Allergy 1998;28:616-24
72. Salek-Ardakani S, Arrand JR, Shaw D, et al. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood 2000;96:1879-88
73. Hasan M, Najjam S, Gordon MY, et al. IL-12 is a heparin-binding cytokine. J Immunol 1999;162:1064-70
74. Salas Martínez A, Sansi Cuffí M, Soriano A, et al. Heparin attenuates TNF-Alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96
75. Koopmann W, Krangel MS. Identification of a glycosaminoglycanbinding site in chemokine macrophage inflammatory protein-1alpha. J Biol Chem 1997;272:10103-9
76. Koopmann W, Ediriwickrema C, Krangel MS. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1beta. J Immunol 1999;163:2120-7
77. Proudfoot AE, Fritchley S, Borlat F, et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001;276:10620-6
78. Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology 1993;3:271-7
79. Guimond S, Maccarana M, Olwin B, et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993;268:23906-14
80. Martino MM, Briquez PS, Ranga A, et al. Heparin-binding domain of fibrin (ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci USA 2013;110:4563-8
81. Ermolieff J, Duranton J, Petitou M, et al. Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: Potent effect of O-butyrylated heparin. Biochem J 1998;330:1369-74
82. Redini F, Tixier J, Petitou M, et al. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 1988;252:515-19
83. Fath MA, Wu X, Hileman RE, et al. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J Biol Chem 1998;273:13563-9
84. Butterworth AE, Wassom DL, Gleich GJ, et al. Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol 1979;122:221-9
85. Nilsson L, Peterson C, Venge P, et al. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating. Ann Thorac Surg 1995;59:713-16
86. Page C. Heparin and related drugs: Beyond anticoagulant activity. ISRN Pharmacol 2013;2013:910743
87. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;368:780-93
88. Kilfeather S, Tagoe S, Perez A, et al. Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br J Pharmacol 1995;114:1442-6
89. Wright T, Castellot J, Petitou M, et al. Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge. J Biol Chem 1989;264:1534-42
90. Castellot JJ, Karnovsky MJ, Beeler DL, et al. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984;120:315-20
91. Fryer A, Huang Y-C, Rao G, et al. Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther 1997;282:208-19
92. Besner GE, Whelton D, Crissman-Combs MA, et al. Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: Modulation by heparin, heparinase, or synthetic heparinbinding HB-EGF fragments. Growth Factors 1992;7:289-96
93. Kalmes A, Vesti BR, Daum G, et al. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 2000;87:92-8
94. Dolowitz D, Dougherty T. The use of heparin as an anti-inflammatory agent. Laryngoscope 1960;70:873
95. Ceyhan B, Celikel T. Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 1995;107:1009-12
96. Crimi N, Armato F, Lamicela M, et al. Inhibitory effect of heparin on eosinophil recruitment after nasal allergen challenge. Eur Respir J 1995;8:10s 97
97. Bendstrup KE, Chambers CB, Jensen JI, et al. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. Am J Respir Crit Care Med 1999;160:1653-8
98. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998;34:135-54
99. Baughman RA, Kapoor SC, Agarwal RK, et al. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 1998;98:1610-15
100. Ahmed T, Smith G, Abraham WM. Effect of oral and intravenous heparin tetrasaccharide on allergic airway responses: Critical role of N-sulfation. Pulm Pharmacol Ther 2013;26:180-8
101. Shastri MD, Johns C, Hutchinson JP, et al. Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties. Anal Bioanal Chem 2013;405:6043-52
102. O'Donnell W, Rosenberg M, Kelleher K, et al. Inhaled heparin does not protect asthmatics against antigen-induced bronchoconstriction. Am Rev Respir Dis 1992;145:A422
103. Pavord I, Mudassar T, Bennett J, et al. The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Eur Respir J 1996;9:217-19
104. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb Haemost 2006;95:535
105. Simonis D, Christ K, Alban S, et al. Affinity and kinetics of different heparins binding to P-And L-selectin. Semin Thromb Hemost 2007;33:534-9
106. Chande N, MacDonald JK, Wang JJ, et al. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: A Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis 2011;17:1979-86
107. Hodak E, Yosipovitch G, David M, et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: A preliminary report. J Am Acad Dermatol 1998;38:564-8
108. Pervin A, Alhakim A, Linhardt R. Separation of glycosaminoglycan-derived oligosaccharides by capillary electrophoresis using reverse polarity. Anal Biochem 1994;221:182-8
109. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109
110. Fareed J, Jeske W, Hoppensteadt D, et al. Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998;82:3L-10L
111. Patel RP, Narkowicz C, Hutchinson JP, et al. A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J Pharm Biomed Anal 2008;46:30-5
112. Kennedy TP. Methods of treating acute exacerbations of chronic obstructive pulmonary disease. 20090054374; 2008
113. Turnbull JE, Fernig D, Ke Y, et al. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992;267:10337-41
114. Patel RP, Narkowicz C, Jacobson GA. Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci 2009;98:1700-11
115. Patel RP, Narkowicz C, Jacobson GA. Investigation of freezing-And thawing-induced biological, chemical, and physical changes to enoxaparin solution. J Pharm Sci 2009;98:1118-28
116. Patel RP, Narkowicz C, Jacobson GA. Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins. Anal Biochem 2009;387:113-21
117. Langeslay DJ, Urso E, Gardini C, et al. Reversed-phase ion-pair ultra-highperformance-liquid chromatography-mass spectrometry for fingerprinting low-molecular-weight heparins. J Chromatogr A 2013;1292:201-10
118. Moncada S, Higgs A. The L-Arginine-nitric oxide pathway. N Engl J Med 1993;329:2002
119. Wraight JM, Smith AD, Cowan JO, et al. Adverse effects of short-Acting beta-Agonists: Potential impact when anti-inflammatory therapy is inadequate. Respirology 2004;9:215-21
120. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-Agonist treatment in bronchial asthma. Lancet 1990;336:1391-6
121. Gibson PG, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroidtreated asthma. J Allergy Clin immunol 2000;105:752-9
122. Djukanović R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74
123. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208
124. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5
125. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: A meta-Analysis. Pediatrics 2000;106:E8
126. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 1996;153:1702-7
127. Antczak M, Kuna P. Heparin inhibits allergen induced airway response in asthmatics. Results of a double blind placebo-controlled crossover study [abstract]. J Allergy Clin Immunol 1995;95:386